⚠ SAFETY NOTICE
If you or someone you love is in immediate danger, call 911.
If you’re having thoughts of suicide or are in emotional crisis, call or text 988 to reach the Suicide & Crisis Lifeline.
The Mental Health Hotline offers support and resources and isn’t a substitute for emergency services.
QUICK ANSWER
Treatment-resistant depression generally describes major depression that hasn’t improved after two antidepressant trials at an adequate dose and duration. It affects a substantial share of people with depression, but it doesn’t mean you’ve run out of treatment options. After two unsuccessful trials, a prescriber may consider adjusting or switching medication, adding another medication, TMS, esketamine or ECT. It’s also worth taking another careful look at the original diagnosis.
If you’ve taken two or three antidepressants and still feel much the way you did before you started, it’s easy to wonder whether you’re the problem. You’re not. Treatment-resistant depression is a recognized clinical situation with its own research and a specific set of next steps. Not responding to the first or second medication doesn’t mean there aren’t other options.
What follows is a map of those next steps, including questions worth asking before you accept the treatment-resistant label. Bring them to a prescriber rather than acting on them alone. The goal is to walk into that appointment knowing what options exist.
What “Treatment-Resistant” Actually Means
A commonly used definition is major depression that doesn’t remit after two trials of antidepressant medication taken at an adequate dose for an adequate length of time. The definition isn’t fully standardized, so clinics and insurers may apply it somewhat differently. That can matter when treatment coverage depends on documentation.
Two parts of that definition matter most: dose and duration. An adequate dose means the medication reached a therapeutic dose instead of stopping at a starting dose. Adequate duration depends on the medication, dose, adherence and clinical circumstances, which is why a prescriber should review each trial before deciding it truly failed.
Around 30% of people with major depression may meet commonly used criteria for treatment-resistant depression. The large STAR*D trial found that remission rates dropped with each additional treatment step: roughly 37% of participants reached remission on the first medication, compared with about 14% by the third-line treatment. Those declining rates are one reason clinicians may start discussing augmentation or other treatment approaches after multiple unsuccessful trials.
Before You Accept the Label: Four Things Worth Ruling Out
Clinicians use the term pseudoresistance when depression looks treatment-resistant but there may be another reason treatment hasn’t worked as expected. Before accepting the label, it’s worth asking your prescriber to walk through a few questions with you.
1. Were the Trials Actually Adequate?
Write out your full medication history before your next appointment: each drug, the highest dose you reached, how long you took it, why you stopped and what side effects you experienced. A medication that seems to have failed may not have reached an adequate dose or duration. Having that history written down can also help when previous treatments need to be documented for options such as TMS or esketamine.
2. Is the Diagnosis Right?
If depression isn’t responding to antidepressants, it may be worth taking another look at the diagnosis. Bipolar disorder, for example, can first appear as a depressive episode and requires a different treatment approach than unipolar depression. ADHD, PTSD and long-standing trauma can also affect symptoms and treatment planning. A diagnostic reassessment isn’t a step backward. It may help clarify what treatment makes sense next.
3. Is Something Medical or Substance-Related in the Way?
Thyroid dysfunction, low vitamin B12 or iron, untreated sleep apnea, chronic pain and certain medications may affect depression symptoms or treatment response. Alcohol or other substance use can matter too. When depression and substance use occur together, both should be addressed as part of the treatment plan.
4. Has Therapy Been Part of the Plan?
Medication and therapy together can improve outcomes for many people with depression. If therapy hasn’t been part of your treatment, or if you tried it once and had a bad experience, that doesn’t mean the door is closed. Cognitive behavioral therapy has a strong evidence base for depression, though it isn’t the only approach. Sometimes the issue is the therapist, the type of therapy or simply the timing.
The Options After Two Failed Trials
Once pseudoresistance has been ruled out, there are more options than many people expect. The table below gives you the main approaches to ask about by name. Which one fits depends on symptom severity, medical history, insurance, how quickly relief is needed and what you’ve already tried. That’s a decision to make with a prescriber. Transcranial magnetic stimulation and other interventional treatments may also require documentation of previous medication trials for insurance coverage.
| Approach | What It Involves | Where It Happens | Worth Knowing |
|---|---|---|---|
| Optimize the current medication | Raising the dose into the therapeutic range or giving the medication enough time before deciding it hasn’t worked | Your prescriber’s office | A medication may look ineffective if the dose or duration wasn’t adequate |
| Switch antidepressants | Moving to a different medication, sometimes in a different class, with the change managed by your prescriber | Your prescriber’s office | Remission rates tend to decline with later treatment steps, which is one reason other strategies may enter the conversation |
| Augment | Adding another medication to the antidepressant you’re already taking. Lithium, thyroid hormone and several atypical antipsychotics may be used this way | Your prescriber’s office, with lab monitoring for some options | Lumateperone joined the FDA-approved add-on options for major depressive disorder in November 2025. Each option has its own side-effect profile to review |
| Add or change psychotherapy | Adding structured therapy to medication or trying a different approach if the previous fit was poor | Outpatient, in person or by telehealth | Therapy can improve outcomes for many people, and one poor experience doesn’t mean therapy can’t help |
| Transcranial magnetic stimulation (TMS) | Magnetic pulses are delivered to a targeted brain region over a series of outpatient sessions. No anesthesia is used | Outpatient clinic | TMS is generally well tolerated and doesn’t carry the same memory-effect concerns as ECT |
| Esketamine nasal spray | A supervised in-clinic dose followed by a monitoring period. Treatment starts more frequently and then tapers | Certified clinic under a federal safety program | FDA-approved for treatment-resistant depression since 2019 and approved for use on its own as of January 2025. It isn’t taken home |
| IV ketamine | Infusions are given in a monitored setting over a series of treatments | Infusion clinic or hospital | Used off-label for depression, so coverage and clinic practices vary. Ask who supervises treatment and what follow-up care is provided |
| Electroconvulsive therapy (ECT) | A brief, controlled seizure is induced under general anesthesia over a series of treatments | Hospital or specialized outpatient center | ECT is among the most effective options for severe treatment-resistant depression, with remission rates commonly reported between 50% and 70%. Memory effects are an important tradeoff to discuss |
ON COST AND ACCESS
The interventional options can carry real logistical weight: repeated appointments for TMS, supervised dosing and monitoring with esketamine, and anesthesia and transportation needs with ECT. Coverage varies by plan and location, and prior authorization may be required. Ask the clinic’s billing staff for a written estimate and ask your insurer what documentation they need before you commit to a course. It can also help to understand what your insurance covers before the first appointment.
What’s Newer, and What’s Still in Trials
The treatment landscape for depression has changed considerably in the past few years, which is worth knowing if your last serious conversation about options was a while ago.
- Esketamine as a standalone treatment. Approved in 2019 only in combination with an oral antidepressant, esketamine received approval for use on its own for treatment-resistant depression in January 2025. The clinic-based administration and monitoring requirements didn’t change.
- Lumateperone as an add-on. In November 2025, the FDA approved lumateperone as an adjunctive therapy alongside antidepressants for major depressive disorder, adding another option to the augmentation list.
- Accelerated TMS protocols. Some accelerated protocols deliver treatment over several days rather than several weeks. Availability and insurance coverage vary, but it’s a reasonable option to ask a TMS provider about.
- Psilocybin-assisted therapy. Psilocybin remains investigational for treatment-resistant depression. Earlier studies have shown promising but mixed results, and phase 3 trials are underway. It isn’t an approved treatment.
How to Push the Process Forward
Moving treatment-resistant depression care forward can depend partly on who is managing your treatment, which can be a lot to navigate when you’re already dealing with depression.
- Get to a psychiatrist. Primary care clinicians prescribe antidepressants for many people. After two unsuccessful trials, a psychiatrist may be able to offer more experience with augmentation and interventional treatments.
- Ask about a mood disorder clinic. Academic medical centers may have specialty programs for people whose depression hasn’t responded to standard treatments. Some offer consultations even when ongoing care remains local.
- Bring the written history. A complete medication history can save time and help prevent repeating a treatment you’ve already tried.
- Ask what happens if this doesn’t work. Knowing the next step can help you understand whether your clinician is planning treatment as a sequence rather than considering one option at a time.
- Consider a second opinion. Getting another opinion is routine in medicine and doesn’t have to be a judgment on your current clinician. A fresh diagnostic review may identify something worth reconsidering.
Getting Through the Search
The stretch between treatments can be its own kind of hard. Each new medication may come with weeks of waiting to find out whether this one will be different, and the disappointment can feel heavier each time something doesn’t work. If you’re feeling discouraged or worn down by the process, bring that into your appointments too. It matters.
Treatment-resistant depression is also associated with a higher risk of suicidal thinking than depression that responds to a first-line treatment. If your thoughts are moving in that direction, tell your treatment team and call or text 988 to reach the Suicide & Crisis Lifeline. If symptoms escalate to the point where safety at home is uncertain, hospital care for depression may be appropriate.
It’s also worth remembering what the treatment data don’t say. Response rates fall as treatment trials accumulate, but they don’t fall to zero. A lack of response so far doesn’t tell you exactly how you’ll respond to a different medication strategy, TMS, esketamine, ECT or a reassessment of the diagnosis. There are still options to discuss.
Where to Find Support
Finding a provider who works with treatment-resistant depression takes legwork, and these resources can shorten the search:
- Mental Health Hotline. 866-903-3787. A free, 24/7 line for information about mental health treatment options and help finding providers. Calls may be answered by an automated assistant, and you can share as much or as little as you want.
- 988 Suicide & Crisis Lifeline. Call or text 988 at any time if you’re in emotional crisis or having thoughts of suicide.
- NAMI HelpLine. 1-800-950-6264. Information, resource referrals and peer support from the National Alliance on Mental Illness, including local affiliate support groups. Available Monday through Friday, 10 a.m. to 10 p.m. ET, and closed on federal holidays. It is not a crisis line.
It can also help to read more broadly about depression and the range of treatment approaches available, particularly if your last thorough conversation about options was several years ago.
Frequently Asked Questions
Two adequate antidepressant trials are a commonly used threshold. Whether a trial counts as adequate depends on the medication, dose, duration, adherence and clinical circumstances, which is why a detailed medication history matters.
No. It describes what hasn’t worked so far, not what will or won’t work next. Some people who don’t respond to several antidepressants may respond to augmentation, TMS, esketamine or ECT. Others may improve after a missed diagnosis or medical factor is identified and addressed.
They serve different situations. ECT has higher reported remission rates and may be considered for severe or urgent cases, but it requires anesthesia and can affect memory. TMS is an outpatient treatment that doesn’t require anesthesia. A psychiatrist can help weigh symptom severity, medical history, urgency and other factors with you.
They’re related but not identical. Esketamine is an FDA-approved nasal spray for treatment-resistant depression and is given in a supervised clinical setting. IV ketamine is used off-label for depression, so practices and insurance coverage can vary. Ask any ketamine clinic about medical supervision, screening and follow-up care.
Often, yes. Many treatments for treatment-resistant depression, including TMS and esketamine, are provided on an outpatient basis. A higher level of care may be needed when symptoms are severe, safety is a concern or your treatment team recommends closer monitoring.
Getting Help for Depression That Hasn’t Responded to Treatment
Trying medication after medication without relief can be exhausting. After a while, even making another appointment can feel like one more thing you don’t have the energy for.
There are still treatment strategies to discuss after two unsuccessful trials. A provider with experience treating treatment-resistant depression can help you look at what you’ve already tried, what may have been missed and which options make sense from here.
Call the Mental Health Hotline at 866-903-3787 for information about depression treatment options and help finding providers in your area. The line is free, available 24/7 and open to you or someone supporting you.
Sources
- Rush, A.J., et al. STAR*D Outcomes. “Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.” American Journal of Psychiatry, 2006.
- McIntyre, R.S., et al. Treatment-Resistant Depression: definition, prevalence, detection, management and investigational interventions. World Psychiatry, 2023.
- U.S. Food and Drug Administration. Spravato Prescribing Information and Risk Evaluation and Mitigation Strategy program materials.
- U.S. Food and Drug Administration. CAPLYTA Prescribing Information.
- Johnson & Johnson. FDA Approval of CAPLYTA. News release, November 6, 2025.
- Reif, A., et al. Esketamine Versus Quetiapine for treatment-resistant depression. New England Journal of Medicine, 2023.
- American Psychiatric Association. Practice guidance on electroconvulsive therapy and neuromodulation for major depressive disorder.
- National Institute of Mental Health. Brain Stimulation Therapies.
- Cuijpers, P., et al. Combined Depression Treatment: psychotherapy, pharmacotherapy and their combination. World Psychiatry, 2020.
- Cole, E.J., et al. Stanford Neuromodulation Therapy: a double-blind randomized controlled trial. American Journal of Psychiatry, 2022.
- Goodwin, G.M., et al. Single-Dose Psilocybin for a treatment-resistant episode of major depression. New England Journal of Medicine, 2022.
- ClinicalTrials.gov. COMP360 Phase 3 Trial in treatment-resistant depression.
- Treatment-resistant depression review. ECT Remission Rates.
- RECOVER trial report. TRD Outcomes and Risk.
